Illustration of a doctor discussing positive kidney treatment results with a patient using digital graphs.
Hoton da AI ya samar

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

Hoton da AI ya samar
An Binciki Gaskiya
Hausa

New data presented at the European Renal Association’s 63rd Congress in Glasgow and published in three major medical journals found that finerenone slowed kidney-function decline in adults with chronic kidney disease (CKD) without diabetes and reduced the risk of a combined kidney-and-cardiovascular outcome. A separate pooled analysis that combined results across finerenone studies also reported fewer kidney and heart-failure events in a broader CKD population.

Researchers reported the results at the European Renal Association (ERA) 63rd Congress in Glasgow, Scotland, with simultaneous publications tied to the presentations in The New England Journal of Medicine, JAMA and The Lancet.

Abin da mutane ke faɗa

Initial reactions on X highlight positive findings from the FIND-CKD trial showing finerenone slows eGFR decline in non-diabetic CKD patients, with 23% risk reduction in kidney and CV events, and similar benefits in pooled analyses across broader CKD populations. Medical professionals and journals express enthusiasm for expanded indications beyond diabetes.

Labaran da ke da alaƙa

Clinical illustration of nurse giving single-dose zilebesiran injection to hypertension patient, with blood pressure monitor showing reduction from KARDIA-2 trial results.
Hoton da AI ya samar

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya

A single, under-the-skin dose of the investigational RNA-interference drug zilebesiran lowered blood pressure when added to standard therapy in adults whose hypertension remained uncontrolled, according to results from the global Phase 2 KARDIA-2 trial of 663 participants published in JAMA.

FDA approves Travere Therapeutics' FILSPARI for FSGS

The U.S. Food and Drug Administration approved FILSPARI, developed by Travere Therapeutics, as the first medicine for focal segmental glomerulosclerosis (FSGS). Travere announced the approval on April 13, 2026. Company executives held a business update conference call that evening to discuss the milestone.

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

An Ruwaito ta hanyar AI An Binciki Gaskiya

Researchers in Barcelona report that the lipid drug pemafibrate and the blood-pressure medicine telmisartan reduced diet-induced liver fat in rats and in a zebrafish model of fatty liver disease, with a half-dose combination performing as well as full doses of either drug alone. The work, published in Pharmacological Research, also describes a role for the PCK1 protein in telmisartan’s liver effects and argues that clinical trials would be needed to confirm any benefit in people.

Lafiya

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

Lafiya

Enlicitide pill reduces LDL cholesterol by 60% in phase 3 trial

Lafiya

Longevity startup doses first patient in vision loss trial

Trial finds metformin may let adults with type 1 diabetes use less insulin without improving insulin resistance

A randomized, placebo-controlled trial led by Australia’s Garvan Institute of Medical Research found that metformin, a long-used and low-cost drug for type 2 diabetes, did not improve clamp-measured insulin resistance in adults with type 1 diabetes but was associated with roughly 12% lower insulin requirements while blood sugar measures remained broadly unchanged.

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

An Ruwaito ta hanyar AI

Researchers from Mass General Brigham found that the cholesterol drug evolocumab cuts the risk of first-time major cardiovascular events by 31% in high-risk patients with diabetes who lack diagnosed atherosclerosis. The results, from a subgroup analysis of the VESALIUS-CV trial, were presented at the American College of Cardiology's Annual Scientific Session and published in JAMA. Patients on the drug saw LDL cholesterol levels drop significantly alongside standard treatments.

May 28, 2026 16:21

Gene-editing drug slashes bad cholesterol 62 percent in trial

May 25, 2026 16:39

Study finds beta blockers offer no benefit after uncomplicated heart attacks

May 21, 2026 22:41

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

May 06, 2026 06:50

Innovative Cape Town clinic boosts outcomes for young kidney patients

May 01, 2026 10:29

Smart water bottles and coaching increased hydration but did not cut kidney stone recurrences, trial finds

April 15, 2026 12:08

Hitting urate targets with gout-lowering therapy is linked to lower cardiovascular risk in large UK study

April 09, 2026 23:54

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Wannan shafin yana amfani da cookies

Muna amfani da cookies don nazari don inganta shafin mu. Karanta manufar sirri mu don ƙarin bayani.
Ƙi